Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Inflammatory bowel disease (IBD), as do most chronic inflammatory disorders, displays
unique features and confers different risk factors in male and female patients. Importantly …

This is the second European Crohn's and Colitis Organisation [ECCO] evidence-based
consensus on extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] and …

Chronic inflammatory diseases including human immunodeficiency virus infection, psoriasis,
rheumatoid arthritis, and systemic lupus erythematosus predispose to atherosclerotic …

Background Emerging data showed patients with chronic inflammatory disorders, including
inflammatory bowel disease, are more likely to develop atherosclerotic cardiovascular …

ABSTRACT Background and Aims Recent studies raise concern for increased risk of major
adverse cardiovascular events (MACE) with Janus kinase inhibitors (JAKi) used to treat …

Background & Aims Population-based studies have suggested an increased risk of acute
arterial events (AAEs) in patients with inflammatory bowel disease (IBD). We aimed to …

Background & Aims The risk of serious infections associated with vedolizumab in patients
with inflammatory bowel disease (IBD) is uncertain. We assessed the risk of serious …

Importance Observational comparative effectiveness studies can inform the positioning of
biologic therapies for older patients with inflammatory bowel disease (IBD) who are …

Objective While infliximab combined to thiopurines is more effective than infliximab
monotherapy in patients with Crohn's disease (CD) and UC, the impact of adding …